Home › Companies › ABEONA THERAPEUTICS INC. › 2024-2025
At ABEONA THERAPEUTICS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held December 20, 2024 and May 19, 2025), 61 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 206 separate fund positions. On the most widely held item of the season, voted at the meeting held May 19, 2025 — To approve, on an advisory basis, the compensation of the Company's named executive officers. — ABEONA THERAPEUTICS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ABEONA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 19, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ABEONA THERAPEUTICS INC.’s Form 8-K, filed May 19, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 19, 2025: 5 items on ABEONA THERAPEUTICS INC.’s Form 8-K, filed May 19, 2025: 3 elected · 2 approved.
Meeting of December 20, 2024: 2 items on ABEONA THERAPEUTICS INC.’s Form 8-K, filed December 20, 2024: 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore ABEONA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ABEONA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. ABEONA THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark J. Alvino | 26,260,868 | 1,143,117 | 31,150 | -- | 7,020,555 | 96% | Elected | — |
| Elect Director: Faith L. Charles | 26,774,705 | 629,378 | 31,052 | -- | 7,020,555 | 98% | Elected | — |
| Elect Director: Donald A. Wuchterl | 26,856,990 | 546,976 | 31,169 | -- | 7,020,555 | 98% | Elected | — |
| 2. Advisory Vote on Compensation of Named Executive Officers | 25,777,223 | 1,552,881 | 105,031 | -- | 7,020,555 | 94% | Approved | — |
| 3. Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm | 34,334,516 | 30,147 | 91,027 | -- | -- | 99.9% | Approved | — |
Source: ABEONA THERAPEUTICS INC., Form 8-K, filed with the SEC on May 19, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Approval of an Increase in the Number of Shares Reserved for Issuance Under the Second A&R Plan | 20,996,641 | 2,876,261 | 695,077 | -- | 0 | 88% | Approved | — |
| 2. Approval of Possible Adjournment of the Special Meeting | 21,642,686 | 2,855,992 | 69,301 | -- | 0 | 88% | Approved | — |
Source: ABEONA THERAPEUTICS INC., Form 8-K, filed with the SEC on December 20, 2024 — read the filing on EDGAR.
Each item below shows how the 61 asset managers that disclosed a ABEONA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held May 19, 2025.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of three Class 3 Directors for a three-year term: Donald A. Wuchterl
ABEONA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Donald A. Wuchterl”): 26,856,990 for, 546,976 against, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Mark J. Alvino, Faith L. Charles and Donald A. Wuchterl were elected to serve as Class 3 directors of the Company until the 2028 annual meeting of stockholders and until their successors are elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 2,708,803 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,995,487 | 0 | 0 | 0 | For |
| Fidelity | 410,044 | 0 | 0 | 0 | For |
| Aberdeen | 224,356 | 0 | 0 | 0 | For |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 18,334 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 11,519 | 0 | 0 | 0 | For |
| Equitable | 7,081 | 0 | 0 | 0 | For |
| Goldman Sachs | 6,732 | 0 | 0 | 0 | For |
| BlackRock | 5,497 | 0 | 0 | 0 | For |
| Victory Capital | 4,629 | 0 | 0 | 0 | For |
| John Hancock | 744 | 0 | 0 | 0 | For |
| State Street | 509 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 21 | 0 | 0 | 0 | For |
Meeting held May 19, 2025.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of three Class 3 Directors for a three-year term: Faith L. Charles
ABEONA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Faith L. Charles”): 26,774,705 for, 629,378 against, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Mark J. Alvino, Faith L. Charles and Donald A. Wuchterl were elected to serve as Class 3 directors of the Company until the 2028 annual meeting of stockholders and until their successors are elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 2,708,294 for, 509 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,995,487 | 0 | 0 | 0 | For |
| Fidelity | 410,044 | 0 | 0 | 0 | For |
| Aberdeen | 224,356 | 0 | 0 | 0 | For |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 18,334 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 11,519 | 0 | 0 | 0 | For |
| Equitable | 7,081 | 0 | 0 | 0 | For |
| Goldman Sachs | 6,732 | 0 | 0 | 0 | For |
| BlackRock | 5,497 | 0 | 0 | 0 | For |
| Victory Capital | 4,629 | 0 | 0 | 0 | For |
| John Hancock | 744 | 0 | 0 | 0 | For |
| State Street | 0 | 509 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 21 | 0 | 0 | 0 | For |
Meeting held May 19, 2025.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of three Class 3 Directors for a three-year term: Mark J. Alvino
ABEONA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark J. Alvino”): 26,260,868 for, 1,143,117 against, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Mark J. Alvino, Faith L. Charles and Donald A. Wuchterl were elected to serve as Class 3 directors of the Company until the 2028 annual meeting of stockholders and until their successors are elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 13 asset managers below reported 2,471,848 for, 236,955 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,995,487 | 0 | 0 | 0 | For |
| Fidelity | 410,044 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 224,356 | 0 | 0 | Against |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 18,334 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 11,519 | 0 | 0 | 0 | For |
| Equitable | 0 | 7,081 | 0 | 0 | Against |
| Goldman Sachs | 6,732 | 0 | 0 | 0 | For |
| BlackRock | 0 | 5,497 | 0 | 0 | Against |
| Victory Capital | 4,629 | 0 | 0 | 0 | For |
| John Hancock | 744 | 0 | 0 | 0 | For |
| State Street | 509 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 0 | 21 | 0 | 0 | Against |
Meeting held December 20, 2024.
88% Approved · of votes cast
Description as filed by funds: To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1.
ABEONA THERAPEUTICS INC.’s own tally for this item (“2. Approval of Possible Adjournment of the Special Meeting”): 21,642,686 for, 2,855,992 against — passed, per its Form 8-K filed December 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Approval of Possible Adjournment of the Special Meeting”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 2,788,771 for, 24,372 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,964,568 | 0 | 0 | 0 | For |
| Fidelity | 403,624 | 0 | 0 | 0 | For |
| Aberdeen | 326,995 | 0 | 0 | 0 | For |
| BlackRock | 62,075 | 0 | 0 | 0 | For |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 19,065 | 0 | 0 | Against |
| Equitable | 7,638 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 4,933 | 0 | 0 | Against |
| John Hancock | 0 | 374 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 21 | 0 | 0 | 0 | For |
Meeting held December 20, 2024.
88% Approved · of votes cast
Description as filed by funds: To approve an increase in the number of shares reserved for issuance under the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares.
ABEONA THERAPEUTICS INC.’s own tally for this item (“1. Approval of an Increase in the Number of Shares Reserved for Issuance Under the Second A&R Plan”): 20,996,641 for, 2,876,261 against — passed, per its Form 8-K filed December 20, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: Approval of an Increase in the Number of Shares Reserved for Issuance Under the Second A&R Plan”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 2,788,771 for, 24,372 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,964,568 | 0 | 0 | 0 | For |
| Fidelity | 403,624 | 0 | 0 | 0 | For |
| Aberdeen | 326,995 | 0 | 0 | 0 | For |
| BlackRock | 62,075 | 0 | 0 | 0 | For |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 19,065 | 0 | 0 | Against |
| Equitable | 7,638 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 4,933 | 0 | 0 | Against |
| John Hancock | 0 | 374 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 21 | 0 | 0 | 0 | For |
Meeting held May 19, 2025.
Combines 6 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
ABEONA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote on Compensation of Named Executive Officers”): 25,777,223 for, 1,552,881 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “An advisory vote to approve the compensation of the Company's named executive officers was approved by the following votes:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,995,487 | 0 | 0 | 0 | For |
| Fidelity | 410,044 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 408,584 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 224,356 | 0 | 0 | Against |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 18,334 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 11,519 | 0 | 0 | 0 | For |
| Equitable | 7,081 | 0 | 0 | 0 | For |
| Goldman Sachs | 6,732 | 0 | 0 | 0 | For |
| BlackRock | 5,497 | 0 | 0 | 0 | For |
| Victory Capital | 4,629 | 0 | 0 | 0 | For |
| John Hancock | 744 | 0 | 0 | 0 | For |
| State Street | 509 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 21 | 0 | 0 | 0 | For |
Fund voting reports, all 14 managers: 2,893,031 for, 224,356 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,278,166 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 3,173,877 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,127,283 | 0 | 0 | 0 | For |
| Western Standard LLC | 2,125,999 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 1,842,751 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 1,306,589 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 267,485 | 216,000 | 0 | 0 | Mixed |
| Newtyn Management, LLC | 480,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 478,973 | 0 | 0 | 0 | For |
| BlackRock | 332,644 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 254,360 | 0 | 0 | Against |
| Aberdeen | 0 | 224,356 | 0 | 0 | Against |
| Newton Investment Management North America, LLC | 116,600 | 0 | 0 | 0 | For |
| Northern Trust | 116,501 | 0 | 0 | 0 | For |
| Wellington | 0 | 111,139 | 0 | 0 | Against |
| Palo Alto Investors LP | 108,865 | 0 | 0 | 0 | For |
| Renaissance | 89,978 | 0 | 0 | 0 | For |
| Citadel | 84,835 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 72,200 | 0 | 0 | 0 | For |
| State Street | 70,859 | 0 | 0 | 0 | For |
| Connective Capital Management, LLC | 65,072 | 0 | 0 | 0 | For |
| Vanguard | 24,804 | 0 | 0 | 0 | For |
| Charles Schwab | 24,370 | 0 | 0 | 0 | For |
| PARK NATIONAL CORP /OH/ | 15,000 | 0 | 0 | 0 | For |
| Argent Trust Co | 10,459 | 0 | 0 | 0 | For |
Institutional-manager reports, all 53 managers: 17,255,907 for, 819,176 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held May 19, 2025.
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: Ratify the appointment of Deloitte & Touche LLP as our independent registered public accountant for the fiscal year ending December 31, 2025.
ABEONA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm”): 34,334,516 for, 30,147 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “A proposal to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 was approved by the following votes:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 3,117,387 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,995,487 | 0 | 0 | 0 | For |
| Fidelity | 410,044 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 408,584 | 0 | 0 | 0 | For |
| Aberdeen | 224,356 | 0 | 0 | 0 | For |
| Charles Schwab | 23,850 | 0 | 0 | 0 | For |
| Northern Trust | 18,334 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 11,519 | 0 | 0 | 0 | For |
| Equitable | 7,081 | 0 | 0 | 0 | For |
| Goldman Sachs | 6,732 | 0 | 0 | 0 | For |
| BlackRock | 5,497 | 0 | 0 | 0 | For |
| Victory Capital | 4,629 | 0 | 0 | 0 | For |
| John Hancock | 744 | 0 | 0 | 0 | For |
| State Street | 509 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 21 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,156,736 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.90% |
| 2 | Fidelity | 0.80% |
| 3 | Simplify Exchange Traded Funds | 0.80% |
| 4 | Aberdeen | 0.44% |
| 5 | Charles Schwab | 0.05% |
| 6 | Northern Trust | 0.04% |
| 7 | Exchange Place Advisors Trust | 0.02% |
| 8 | Equitable | 0.01% |
| 9 | Goldman Sachs | 0.01% |
| 10 | BlackRock | 0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 6.41% |
| 2 | Nantahala Capital Management, LLC | 6.20% |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.11% |
| 4 | Western Standard LLC | 4.16% |
| 5 | Vivo Capital, LLC | 3.60% |
| 6 | Laurion Capital Management LP | 2.55% |
| 7 | KENNEDY CAPITAL MANAGEMENT LLC | 0.95% |
| 8 | Newtyn Management, LLC | 0.94% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.94% |
| 10 | BlackRock | 0.65% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Nantahala Capital Management, LLC | 11.29% | 13G |
| Adage Capital Partners, L.P. | 8.23% | DEF14A |
| NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 6.52% | 13G |
| AIGH Capital Management LLC | 6.06% | 13G |
| Funicular Funds, LP | 5.88% | 13G |
| Daniel Kaufman | 5.75% | 13G |
| James Russell Revocable Trust | 5.32% | 13G |
| Suvretta Capital Management, LLC | 5.23% | 13G |
| Vanguard Group | 3.95% | 13F |
| Vishwas Seshadri | 2.74% | DEF14A |
Percentages above are of 51,156,736 shares outstanding, as reported by ABEONA THERAPEUTICS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ABEONA THERAPEUTICS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ABEONA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “ABEONA THERAPEUTICS (ABEO) 2024-2025 Annual & Special Meetings”, https://proxyvotesnow.com/company/abeona-therapeutics-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.